PlaqueTec Ltd., a Cambridge-based company developing a biomarker-based approach designed to transform the understanding of coronary artery disease (CAD), the leading cause of death worldwide, appointed Tim Brears as chief executive officer. Dr. Brears has many years’ experience in the biopharmaceutical industry and was, until recently, chief executive of Xention Limited, a company he founded in 2002 and which has become a leader in the development of drugs for the control of atrial fibrillati...